Tempus paid $1.5B for Personalis despite holding more patents than its target. IP due diligence in acquisitions is about positioning, not portfolio size.
Tempus AI is paying $1.5 billion for Personalis, a company that held fewer MRD liquid biopsy patents than the acquirer itself.
Personalis had been Tempus’s MRD testing partner since 2023, so the target wasn’t a surprise. Tempus had also filed US-20250125050-A1, covering MRD liquid biopsy detection, in April 2025, more than a year before the deal. Before the announcement, Tempus had already built a stronger IP position in this space than Personalis. An acquirer that already holds more IP than its target in the same space is not making a gap-fill acquisition.
The count doesn’t explain why Tempus paid $1.5 billion. Deals close on technology specificity, commercial traction, team, and timing, none of which IP volume alone captures.
The more precise measure is whether your IP position overlaps with what a likely acquirer is already building, and whether you’re in the gap, not competing for the same ground.
The pattern challenges a common assumption: that portfolio size is a reliable signal of acquisition premium. It often isn’t.
Want to map where your IP sits relative to what your most likely acquirer is already building? Talk to ipCapital Group about an IP landscape and positioning analysis.
Work with ipCapital Group
From invention to monetization, our team has guided 2,000+ engagements across the full IP lifecycle. Start with a free 30-minute discovery call.
Written by
John Cronin